(Q37463922)

20 August 2017

1 reference

title

Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma (English)

1 reference

20 August 2017

0 references

Brian I Rini

1

1 reference

PubMed ID

19402073

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

7

1 reference

inferred from page(s)

published in

Cancer

1 reference

20 August 2017

115

1 reference

20 August 2017

10 Suppl

1 reference

20 August 2017

2306-2312

1 reference

Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.

20 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24227

7 January 2021

Identifiers

DOI

10.1002/CNCR.24227

1 reference

20 August 2017

1 reference

PubMed ID

19402073